News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Swiss Approve Novartis International AG Drug For Blindness
August 29, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Europe
MORE ON THIS TOPIC
Manufacturing
Samsung Biologics inks $262M manufacturing deal with European pharma company
September 11, 2026
·
2 min read
·
Nick Paul Taylor
FDA
Biohaven takes another hit as FDA pauses enrollment in pivotal trials for embattled epilepsy drug
September 10, 2026
·
3 min read
·
Heather McKenzie
Manufacturing
Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision
September 9, 2026
·
2 min read
·
Nick Paul Taylor
FDA
Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
September 9, 2026
·
1 min read
·
Jef Akst
